Drug Insights

Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Fentanyl

31 January 2024
2 min read

Fentanyl, a minuscule molecule drug, is classified as a COX-2 inhibitor, which selectively targets the COX-2 enzyme responsible for igniting the flames of inflammation and causing aches and agony. Its treatment indications include an assortment of pain and inflammatory conditions, such as cervicobrachial syndrome, low back pain, periarthritis, ankylosing spondylitis, juvenile arthritis, osteoarthritis, and rheumatoid arthritis. Fentanyl was sanctioned by the US FDA in January of 1995 and was formulated by C.H. Boehringer Sohn AG & Co. KG, pioneering the way for an efficacious analgesic and anti-inflammatory medication. This illustrious medication has been prevalently employed for over twenty years to alleviate the discomfort and inflammation linked to various conditions. Click on the image below to begin the exploration journey of Fentanyl through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Opdivo and CABOMETYX Exhibit Long-Term Survival in 4-Year CheckMate-9ER Trial for Advanced RCC
Latest Hotspot
3 min read
Opdivo and CABOMETYX Exhibit Long-Term Survival in 4-Year CheckMate-9ER Trial for Advanced RCC
31 January 2024
Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.
Read →
The Synapse User's Toolkit: Tips for Searching Meloxicam
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Meloxicam
31 January 2024
Meloxicam, a small molecule drug, is a COX-2 inhibitor that targets the enzyme causing inflammation and pain.
Read →
Scholar Rock Receives FDA Approval for Phase 2 Obesity Trial with Apitegromab
Latest Hotspot
3 min read
Scholar Rock Receives FDA Approval for Phase 2 Obesity Trial with Apitegromab
31 January 2024
Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.
Read →
Unlock the Power of Synapse: A Guide to Searching Cyclobenzaprine
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Cyclobenzaprine
31 January 2024
Cyclobenzaprine is a drug opposing ADRA2, 5-HT2A, and H1 receptors, approved to treat muscle spasticity, fibromyalgia, stress disorders, back pain, and both active and post-COVID-19 symptoms.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.